par Lavis, Philomène 
;Morra, Sofia ;Orte Cano, Carmen;Albayrak, Nurhan ;Corbiere, Véronique ;Olislagers, Véronique ;Dauby, Nicolas ;Del Marmol, Véronique ;Marchant, Arnaud ;Decaestecker, Christine ;Mascart, Françoise ;De Vos, Nathalie ;Van De Borne, Philippe ;Salmon, Isabelle ;Remmelink, Myriam ;Parmentier, Marc ;Cardozo, Alessandra K ;Bondue, Benjamin
Référence Frontiers in immunology, 13, page (941663)
Publication Publié, 2022-11-01
;Morra, Sofia ;Orte Cano, Carmen;Albayrak, Nurhan ;Corbiere, Véronique ;Olislagers, Véronique ;Dauby, Nicolas ;Del Marmol, Véronique ;Marchant, Arnaud ;Decaestecker, Christine ;Mascart, Françoise ;De Vos, Nathalie ;Van De Borne, Philippe ;Salmon, Isabelle ;Remmelink, Myriam ;Parmentier, Marc ;Cardozo, Alessandra K ;Bondue, Benjamin Référence Frontiers in immunology, 13, page (941663)
Publication Publié, 2022-11-01
Article révisé par les pairs
| Résumé : | Chemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties have been observed. The aim of our study was to evaluate the involvement of the chemerin/ChemR23 system in the physiopathology of COVID-19 with a particular focus on its prognostic value. |
